Speichererkrankungen mit kardialer Manifestation

Kardiale Speichererkrankungen stellen eine heterogene Gruppe von Systemerkrankungen dar, bei denen die Ablagerung krankheitsspezifischer Substanzen zu einer fortschreitenden Herzinsuffizienz führt. Aufgrund ihrer Seltenheit werden kardiale Speichererkrankungen im klinischen Alltag häufig erst im fortgeschrittenen Stadium erkannt. Der folgenden Beitrag soll sensibilisieren und stellt Diagnose und Therapieansätze vor, die den Verlauf verzögern können.

Schlüsselwörter

Speichererkrankung - kardial - Amyloidose - Morbus Fabry - Hämochromatose

• Literatur

• 1 Yousef Z, Elliott PM, Cecchi F. et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J 2013; 34: 802-808
• 2 Yilmaz A, Bauersachs J, Bengel F. et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 2021; 110: 479-506
• 3 Garcia-Pavia P, Rapezzi C, Adler Y. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021; 42: 1554-1568
• 4 Pinney JH, Whelan CJ, Petrie A. et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013; 2: e000098
• 5 Ihne S, Morbach C, Sommer C. et al. Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. Dtsch Arztebl Int 2020; 117: 159-166
• 6 Dorbala S, Ando Y, Bokhari S. et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2019; 26: 2065-2123
• 7 Gillmore JD, Maurer MS, Falk RH. et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016; 133: 2404-2412
• 8 Maurer MS, Schwartz JH, Gundapaneni B. et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 379: 1007-1016
• 9 Ternacle J, Krapf L, Mohty D. et al. Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol 2019; 74: 2638-2651
• 10 Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5: 30
• 11 Spada M, Pagliardini S, Yasuda M. et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31-40
• 12 Linhart A, Germain DP, Olivotto I. et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 2020; 22: 1076-1096
• 13 Azevedo O, Cordeiro F, Gago MF. et al. Fabry Disease and the Heart: A Comprehensive Review. Int J Mol Sci 2021; 22: 4434
• 14 Hughes DA, Nicholls K, Shankar SP. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017; 54: 288-296
• 15 Aronow WS. Management of cardiac hemochromatosis. Arch Med Sci 2018; 14: 560-568
• 16 Oudit GY, Sun H, Trivieri MG. et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: 1187-1194
• 17 Fitzsimons EJ, Cullis JO, Thomas DW. et al. Diagnosis and therapy of genetic haemochromatosis (review and 2017 update). Br J Haematol 2018; 181: 293-303
• 18 European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53: 3-22
• 19 Salgia RJ, Brown K. Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis 2015; 19: 187-198
• 20 Kowdley KV, Brown KE, Ahn J. et al. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol 2019; 114: 1202-1218
• 21 McDonagh TA, Metra M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726